Foreign Data: Sintilimab’s Development Shows What Not To Do When Pursuing US Approval
Executive Summary
The FDA’s concerns about conduct of ORIENT-11 trial include adequacy of informed consent, uncertainty about confidence in data generated in China, and failure of development partners Innovent and Eli Lilly to consult the US regulator about the study’s design.
You may also be interested in...
FDA Postmarket Guidance Hammers Home Positions On Foreign Trials, Real-World Evidence
US agency emphasizes and formalizes long-standing viewpoints on hot topics including accelerated approval in a new guidance on postmarket study diversity.
BeiGene’s Tislelizumab Delivers With OS Data In Broad Gastric Cancer Population
The PD-L1 inhibitor partnered with Novartis improved overall survival in combination with chemotherapy in gastric cancer patients regardless of PD-L1 status.
Califf Laments Shift To Ex-US Clinical Trials – As Well As Pace Of Reforms At Home
US FDA commissioner tells J.P. Morgan conference that the agency, industry, and the entire healthcare system need to change ‘at the same time’ in order for clinical trials to improve.